WuXi PharmaTech's Suzhou toxicology facility passes FDA inspection WuXi PharmaTech announced that its toxicology facility in Suzhou recently passed a surveillance Good Laboratory Practice inspection by the FDA with no major observations. This was the first FDA GLP inspection in the facility's five years of operation. The inspection was extensive, lasting five days and including the review of numerous processes and the audit of four studies. WuXi's toxicology facility in Suzhou has completed 92 IND-enabling programs for global submissions.
WuXi PharmaTech downgraded to Hold from Buy at Jefferies Jefferies downgraded WuXi PharmaTech to Hold with a $38 price target saying upcoming margin pressure is not priced into shares or reflected in consensus estimates.